Merck KGaA's Mavenclad stakes its claim in massively competitive MS market.
Autor: | Blankenship, Kyle |
---|---|
Zdroj: | FiercePharma; 3/5/2020, pN.PAG-N.PAG, 1p |
Databáze: | Complementary Index |
Externí odkaz: |
Autor: | Blankenship, Kyle |
---|---|
Zdroj: | FiercePharma; 3/5/2020, pN.PAG-N.PAG, 1p |
Databáze: | Complementary Index |
Externí odkaz: |